Black Bird Biotech Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Black Bird Biotech has been growing earnings at an average annual rate of 63.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 61% per year.
Información clave
63.7%
Tasa de crecimiento de los beneficios
85.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | -61.0% |
| Rentabilidad financiera | n/a |
| Margen neto | -2,301.9% |
| Última actualización de beneficios | 30 Sep 2023 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Black Bird Biotech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -1 | 0 | 0 |
| 30 Jun 23 | 0 | -1 | 0 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -3 | 2 | 0 |
| 31 Mar 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Ingresos de calidad: BBBT is currently unprofitable.
Margen de beneficios creciente: BBBT is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if BBBT's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare BBBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: BBBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rentabilidad financiera
Alta ROE: BBBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.